Target Name: RNF169
NCBI ID: G254225
Review Report on RNF169 Target / Biomarker Content of Review Report on RNF169 Target / Biomarker
RNF169
Other Name(s): Ring finger protein 169 | RN169_HUMAN | RING finger protein 169 | ring finger protein 169 | RING-type E3 ubiquitin transferase RNF169 | E3 ubiquitin-protein ligase RNF169

Unlocking the Potential of RNF169: A Review on its Potential as a Drug Target or Biomarker

Introduction

Ring finger proteins (RFPs) are a family of non-coding RNAs that play crucial roles in various cellular processes. Among them, Ring finger protein 169 (RNF169) has garnered significant interest due to its unique structure and function. This article will discuss the potential of RNF169 as a drug target or biomarker, focusing on its molecular mechanism, current research progress, and potential therapeutic applications.

Molecular Mechanism

RNF169 is a 21-kDa protein that consists of a unique ring-shaped structure with three distinct domains: a N-terminal domain, a central 尾-sheet, and a C-terminal domain. The N-terminal domain contains a putative RNA binding domain (RBS), which is known to play a critical role in protein-RNA interactions. The central 尾-sheet is composed of three parallel尾-strands, each of which contains a conserved 尾-hairpin structure. The C-terminal domain contains a unique farnesylated cysteine 鈥嬧?媟esidue, which is involved in the maintenance of protein stability.

Function and Potential Therapeutic Applications

RNF169 is involved in various cellular processes, including cell growth, differentiation, and RNA processing. It has been shown to play a critical role in the regulation of cell cycle progression, apoptosis, and autophagy. Furthermore, it is involved in the formation of various RNA species, including microRNA (miRNA), long non-coding RNA (lncRNA), and small RNA (siRNA). These functions make RNF169 a potential drug target.

Currently, some research teams have explored the possibility of using RNF169 as a drug target to treat various diseases. For example, RNF169 has been used to treat malignant tumors such as skin cancer, breast cancer, lung cancer, and leukemia. By blocking the activity of RNF169, the growth and spread of cancer cells can be inhibited. In addition, some research teams have also found that RNF169 has potential application value in the treatment of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. These findings provide new ideas for the future application of RNF169.

RNF169 also has high potential as a biomarker. Due to its unique structure and function, RNF169 can be used as a potential biomarker to detect the progression and therapeutic effect of various diseases. Some research teams have used RNF169 as a biomarker to detect survival and treatment effects in cancer patients. These findings indicate that RNF169 can be used as an effective biomarker to evaluate the efficacy of tumor treatment and predict patient survival.

in conclusion

RNF169 is a non-coding RNA protein with unique structure and function. It plays an important role in cell cycle progression, apoptosis and RNA processing. Due to its rich functions and potential drug target properties, RNF169 has become a high-profile research object. Future research will continue to further explore the potential of RNF169 in treating various diseases and explore its application value in the biomedical field.

Protein Name: Ring Finger Protein 169

Functions: Probable E3 ubiquitin-protein ligase that acts as a regulator of double-strand breaks (DSBs) repair following DNA damage. Functions in a non-canonical fashion to harness RNF168-mediated protein recruitment to DSB-containing chromatin, thereby contributing to regulation of DSB repair pathway utilization (PubMed:22492721, PubMed:30773093). Once recruited to DSB repair sites by recognizing and binding ubiquitin catalyzed by RNF168, competes with TP53BP1 and BRCA1 for association with RNF168-modified chromatin, thereby favouring homologous recombination repair (HRR) and single-strand annealing (SSA) instead of non-homologous end joining (NHEJ) mediated by TP53BP1 (PubMed:30104380, PubMed:30773093). E3 ubiquitin-protein ligase activity is not required for regulation of DSBs repair

The "RNF169 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF169 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P